Skip to main content
Premium Trial:

Request an Annual Quote

Fisher s Dharmacon Licenses Kreutzer-Limmer RNAi Patents from Alnylam

NEW YORK, Jan. 5 (GenomeWeb News) - Alnylam has granted Dharmacon a non-exclusive license to its Kreutzer-Limmer patent family, enabling the Fisher unit to develop and sell certain RNAi research products and services covered by the patents, Alnylam said today.


The Kreutzer-Limmer family, owned by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells. Dharmacon is currently a provider of siRNA reagents, and the Alnylam IP  expands its portfolio of internally developed and in-licensed RNAi intellectual property.

Alnylam obtained the rights to the Kreutzer-Limmer patent family, which were awarded in Europe, when it acquired Ribopharma in July 2003. That company is now known as Alnylam Europe. The patent family includes EP Patent No. 1144623, which covers siRNAs up to 25 nucleotides in length having a sequence complementary to a target gene; and EP Patent No. 1214945, which covers compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides.


Patents corresponding to these patents have been issued or are pending in many other countries, Alnylam said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.